Upstream Bio, Inc.
UPBNext catalyst
Verekitug
Severe Asthma
Get an email about UPB's next catalysts
Track Upstream Bio (UPB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (conference, Phase 2 readout).See the timeline
3 upcoming, 2 past
Conference Presentation
Upstream Bio announced participation in upcoming December 2026 investor conferences. No specific details regarding conference dates, locations, or presentation topics were provided.
Verekitug Phase 2 Est. Readout
Estimated primary completion for Verekitug trial (NCT06966479) in Severe Asthma. Topline data typically follows completion by weeks to months.
SourceVerekitug Phase 2 Est. Readout
Primary completion for Verekitug trial (NCT06966479) in Severe Asthma
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Verekitug (UPB-101) | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | - | - |
Verekitug | Phase 2 | Severe Asthma | - | - |
Frequently asked questions
What is in Upstream Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Upstream Bio, Inc.'s (UPB) pipeline across Phase 2. Its lead program is Verekitug (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Upstream Bio, Inc.'s next FDA catalyst?→
Upstream Bio, Inc.'s (UPB) next tracked catalyst is a Phase 2 readout expected September 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UPB biotech catalysts?→
Add UPB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Upstream Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
